Antiocclusive efficacy of TauroLock™

All TauroLock™ lock solutions contain citrate as an anticoagulant. This active ingredient serves to prevent occlusions and maintain a high flow rate over extended periods of time. At a concentration of 4 % (as used in our products), citrate safely removes calcium ions from the blood coagulation cascade. It thereby prevents the coagulation of blood in the catheter, which could lead to impaired patency and catheter dysfunction. For dialysis catheters, antiocclusive properties can be enhanced by the addition of heparin or urokinase.

TauroLock™ is available with different supplements:

• 100 IU/ml heparin (in TauroLock™-HEP100) 
• 500 IU/ml heparin (in TauroLock™-HEP500)
• 5,000 IU/ml urokinase (in TauroLock™-U25.000)

The active ingredient heparin has an additive anticoagulant effect.

For the strongest prophylaxis against catheter occlusion and infection, we recommend using TauroLock™-U25.000 on a regular basis. This lock solution is supplemented with a final concentration of 5,000 IU/ml urokinase. It therefore reduces flow problems within the catheter substantially. Which catheter lock solution works best always depends on the patient’s individual situation. An alternating use of TauroLock™ products (e.g. TauroLock™-HEP500 and TauroLock™-U25.000 in dialysis) is also feasible.